University of Kentucky

UKnowledge
Molecular and Cellular Biochemistry Faculty
Publications

Molecular and Cellular Biochemistry

2-18-2019

Coupling of PARP1-Mediated Chromatin Structural Changes to
Transcriptional RNA Polymerase II Elongation and
Cotranscriptional Splicing
Elena A. Matveeva
University of Kentucky, elmatva@email.uky.edu

Qamar M. H. Al-Tinawi
University of Kentucky

Eric C. Rouchka
University of Louisville

Yvonne N. Fondufe-Mittendorf
University of Kentucky, y.fondufe-mittendorf@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/biochem_facpub
Part of the Biochemistry, Biophysics, and Structural Biology Commons, and the Genetics and
Genomics Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Matveeva, Elena A.; Al-Tinawi, Qamar M. H.; Rouchka, Eric C.; and Fondufe-Mittendorf, Yvonne N.,
"Coupling of PARP1-Mediated Chromatin Structural Changes to Transcriptional RNA Polymerase II
Elongation and Cotranscriptional Splicing" (2019). Molecular and Cellular Biochemistry Faculty
Publications. 164.
https://uknowledge.uky.edu/biochem_facpub/164

This Article is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge.
It has been accepted for inclusion in Molecular and Cellular Biochemistry Faculty Publications by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Coupling of PARP1-Mediated Chromatin Structural Changes to Transcriptional
RNA Polymerase II Elongation and Cotranscriptional Splicing
Digital Object Identifier (DOI)
https://doi.org/10.1186/s13072-019-0261-1

Notes/Citation Information
Published in Epigenetics & Chromatin, v. 12, article no. 15, p. 1-18.
© The Author(s) 2019.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.

This article is available at UKnowledge: https://uknowledge.uky.edu/biochem_facpub/164

(2019) 12:15
Matveeva et al. Epigenetics & Chromatin
https://doi.org/10.1186/s13072-019-0261-1

Epigenetics & Chromatin
Open Access

RESEARCH

Coupling of PARP1‑mediated chromatin
structural changes to transcriptional RNA
polymerase II elongation and cotranscriptional
splicing
Elena A. Matveeva1, Qamar M. H. Al‑Tinawi1,2, Eric C. Rouchka3,4 and Yvonne N. Fondufe‑Mittendorf1*

Abstract
Background: Recently, we showed that PARP1 is involved in cotranscriptional splicing, possibly by bridging chroma‑
tin to RNA and recruiting splicing factors. It also can influence alternative splicing decisions through the regulation of
RNAPII elongation. In this study, we investigated the effect of PARP1-mediated chromatin changes on RNAPII move‑
ment, during transcription and alternative splicing.
Results: We show that RNAPII pauses at PARP1–chromatin structures within the gene body. Knockdown of PARP1
abolishes this RNAPII pausing, suggesting that PARP1 may regulate RNAPII elongation. Additionally, PARP1 alters
nucleosome deposition and histone post-translational modifications at specific exon–intron boundaries, thereby
affecting RNAPII movement. Lastly, genome-wide analyses confirmed that PARP1 influences changes in RNAPII elon‑
gation by either reducing or increasing the rate of RNAPII elongation depending on the chromatin context.
Conclusions: These studies suggest a context-specific effect of PARP1–chromatin binding on RNA polymerase
movement and provide a platform to delineate PARP1’s role in RNA biogenesis and processing.
Keywords: Splicing, RNA polymerase II, Epigenetics, Poly(ADP)ribose polymerase, Polymerase elongation,
Nucleosomes, Chromatin
Introduction
PARP1 also known as ARDT1 belongs to family of proteins known as ADP-ribosylases. This group of enzymes,
up to 17 in humans, have varying degrees of homology
but a highly conserved PARP catalytic domain. These
proteins use NAD+ as a substrate to catalyze the addition of ADP-ribose moiety(ies) onto target proteins,
hence the name ADP-ribosyltransferase. Within this
family, only PARP1 and PARP2 can build “poly”-ADPribose polymers, while the others are capable of adding
only a monomeric ADP-ribose to proteins.
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PARP1 is the most studied of this family of proteins for
which multiple functions been described, which implies
pleiotropic functional characteristics. PARP1 is well
known for its role in DNA-repair, genome integrity, and
cell death [1]. It also adds poly-ADP-ribose (PAR) onto
several proteins involved in NAD+ metabolism [2].
Additionally, for innate immunity, DNA damage, or metabolic stress, PARP1 can act as a coactivator of NF-κB
transcription factors, contributing to the transcription of
a subset of NF-κB target genes [3]. Increasingly, the role
of PARP1 in modulating chromatin structure to regulate
gene expression is being recognized. PARP1 adds PAR
residues (PARylates) onto histones [4], which opens the
chromatin structure and enables gene activation. In support of this function of maintaining active transcription,
several genome-wide studies show PARP1 to be associated with active gene promoters [5, 6], and competing
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with the repressive histone H1 [7, 8] to elicit differential
gene expression outcomes. However, while it is clear
that PARP1 is important in gene activation, other studies
have shown that depletion of PARP1 also results in gene
repression [7–11], suggesting that PARP1 most likely acts
in a context-specific manner.
Regulation of gene expression occurs at both the transcriptional initiation and splicing levels, with chromatin
structure influencing both processes. Interestingly, while
the role of chromatin in transcription has been studied significantly, the role of chromatin in splicing is just
emerging. The recent discovery that splicing, or the decision of a particular region to be spliced, occurs cotranscriptionally while the nascent mRNA is still tethered to
chromatin, developed into the cotranscriptional splicing
hypothesis [12–14]. Indeed, changes to the epigenome
that mediate chromatin structural integrity have been
implicated in alternative splicing regulation. For instance,
DNA methylation and histone modifications demarcate
exon–intron boundaries [13, 15–19] that regulate splicing decisions. It is, therefore, possible that in regulating
chromatin structure, PARP1 might also play a role in this
process. Indeed, our previous study demonstrated a functional role for PARP1 and PARylation in the regulation of
pre-mRNA splicing [5]. We showed that PARP1 binds to
nucleosomes at target exon/intron boundaries, mediating
specific splicing decisions. In addition, we demonstrated
that knockdown of PARP1 or inhibition of its PARylation
activity resulted in changes in specific alternative splicing patterns. Interestingly, splicing products in PARP1
knockdown (KD) cells versus PARylation-inhibited cells
were not similar, possibly suggesting that the effects of
PARP1 on chromatin binding are direct while its PARylation activity is indirect. We therefore hypothesized that
modulation of chromatin structure by PARP1 directly
affects splicing decisions, while its PARylation activity
could regulate splicing through activation of splicing factors [20] and/or through PARylation of histones [1, 21,
22] to open up the chromatin structure. However, a clear
understanding of how PARP1 regulates alternative splicing is unknown.
Two non-mutually exclusive models have been hypothesized to explain how chromatin structure or factors
that modulate chromatin structure, regulate alternative
splicing. (1) The kinetic model proposes that chromatin
structure regulates the speed of polymerase elongation
to influence splicing outcomes [23]. (2) The adaptor/
recruitment model proposes that chromatin or its associated factors recruit splicing factors, bridging the chromatin structure and the nascent mRNA [24–26]. PARP1
could act in both models: PARP1–chromatin binding
is well established, and in addition to this function, we
showed that PARP1–chromatin binds to splicing factor
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3B1 (SF3B1), a U2 spliceosomal member [5], and might
therefore act as an adapter, bringing the splicing complex (with SF3B1) to RNA. As a further step, we showed
that PARP1 binds RNA and identified the PARP1-mRNA
binding landscape [11]. In summary, these data support
the adapter model for PARP1 to regulate splicing. However, it is not implausible that PARP1 also could regulate
the rate of polymerase elongation, especially as PARP1
has been shown to be involved in polymerase pausing
at the promoters of heat shock genes [27]. We therefore
hypothesized that if PARP1 plays a role in polymerase
pausing at the transcription level (promoter region), it
may also play a role in chromatin structure that pauses
RNAPII elongation along the gene body for splicing regulation. In the current study, we propose that PARP1 also
works as an RNAPII regulator through mutual interdependence of splicing and transcription elongation. Using
S2 Drosophila cells as a convenient model (Drosophila
contains only one PARP1 gene), we tested the effect of
PARP1 on the RNAPII elongation rate and cotranscriptional splicing.

Results
PARP1 is involved in mRNA splicing

We previously showed that PARP1 KD in Drosophila S2
cells results in changes in alternative splicing of several
genes [5]. Our goal in this study is to understand mechanistically how PARP1 modulates chromatin structure
to regulate splicing decisions. We chose to analyze this
mechanism in depth at two genes—AKAP200 (hence
called AKAP) and CAPER—because we found that (1)
PARP1 binds to nucleosomes within their gene bodies
and (2) PARP1 depletion correlated with changes in the
splicing decisions observed through RNA-seq genomewide analyses [5] (Fig. 1a). We used RNA interference
to deplete PARP1 in S2 Drosophila cell lines (Additional
file 1: Fig. S1), to assess whether PARP1 binding on AKAP
and CAPER exon–introns reflects a direct role for PARP1
in alternative splicing decisions at these genes. We then
performed PCR with exon junction spanning primers to
validate the splicing changes (Fig. 1b). These results validated the genome-wide studies [5] and showed that in
the absence of PARP1, differentially spliced transcripts
for AKAP and CAPER were produced. Furthermore,
a second siRNA (siRNA2) targeting a different region
of PARP1 (Additional file 1: Fig. S1A and B) confirmed
these results (Additional file 1: Fig. S2). To test whether
this effect is due to PARP1 directly or its enzymatic activity, we inhibited its PARylation using PJ34 (Additional
file 1: Fig. S1C) and showed that PARylation inhibition
effected no changes in splicing at these two target genes
(Additional file 1: Fig. S2).
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a

b

Fig. 1 PARP1 depletion alters splicing decisions. a Sashimi plots showing changes in the splicing decisions due to PARP1 depletion in RNA-seq
genome-wide analyses for AKAP200 and CAPER. b PCR products with exon junction spanning primers validate splicing changes in AKAP200 and
CAPER. Agarose gel images and percentage of exons inclusion show the difference in splicing product between non-treated (WT) and PARP1
knockdown (KD) cells. Actin is shown as a PARP1 non-target gene. Additionally, the percentage of each isoform included is calculated as a
percentage of all transcripts amplified by PCR set to a 100%

PARP1–chromatin structure influences RNA polymerase
elongation

We next tested whether PARP1 regulates splicing
through regulation of the rate of RNAPII elongation. For
this, we used our genome-wide data of PARP1 nucleosome occupancy (GSE56120) in Drosophila S2 cells
with PRO-seq data [28] (GSE42117) of transcriptionally
engaged RNA polymerase. Analyses of these binding
profiles showed that PARP1 and engaged RNAPII are in
close proximity within gene bodies. Indeed, we observe
a shift ~ 25 bp downstream of the PARP1 signal relative
to the RNAPII signal (shown as metagene plots in Additional file 1: Fig. S3). These data suggest that PARP1 may
be involved in RNAPII elongation stalling. Next, we
investigated if these binding profiles are true in our genes
of interest above.

The processivity of RNAPII depends on the phosphorylation state of its carboxy terminal domain (CTD).
In particular, the transition between initiation-pausing
and productive elongation is marked by phosphorylation on Ser5 and Ser2, respectively [29–31]. We therefore asked whether PARP1 influences the recruitment
of different forms of phosphorylated RNAPII to exonic
regions of our target genes, AKAP and CAPER. Three
antibodies that bind specific phosphorylation states
of RNAPII were used: (1) 4H8, which recognizes Ser5
phosphorylation (marks initiating and first regions of
the gene)—hence referred to as Ser5; (2) H5, which recognizes Ser2 phosphorylation is found mainly in the
gene body and toward the 3′ end of the gene. This form
is known as the transcriptionally engaged and elongating form of RNAPII—hence referred to as Ser2P;
(3) 8WG16, which recognizes hypo-phosphorylated
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RNAPII found at pre-initiation sites. The 8WG16 antibody has been reported to sometimes also recognize
Ser5-phosphorylated RNAPII and could be used to
determine total RNAPII. We therefore performed ChIPqPCR using these antibodies on cross-linked chromatin from wild type (WT) and PARP1 knockdown (KD)
cells and analyzed the occupancy of the various forms
of RNAPII on the two PARP1 target genes—AKAP and
CAPER (Fig. 2 and Additional file 1: Fig: S4). To better
assess the correlation between PARP1 reduction and
RNAPII occupancy, we calculated the ratio between the
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occupancies of these polymerase forms and PARP1 at
three locations: (1) the immediate preceding constitutive exon; (2) the intervening intron; (3) the proceeding alternative exon of these genes as shown in Fig. 2a.
We call this the ‘travelled’ index as it determines the
ratio of PARP1 (or RNAPII) occupancy at the proceeding intron or alternative exon, relative to the preceding
constitutive exon.
To begin, the occupancy of PARP1 was measured. In
WT cells, at the AKAP gene, a 22% reduction in the relative occupancy of PARP1 was observed at the alternative

a

b

c

d

e

Fig. 2 PARP1 and RNAPII ChIP-qPCR for PARP1 target genes AKAP200 and CAPER. a Diagram of constitutive (black boxes) and alternative (gray
boxes) exons of a wider region (upper) and zoomed in region (lower) for AKAP200 and CAPER genes. Green arrows depict primer locations. b, c
Showing the relative occupancy of PARP1 in wild type (WT, blue line) and PARP1 knockdown (KD, red line) cells for AKAP200 and CAPER at the
alternative exon relative to presiding constitutive exon. d, e Showing RNAPII occupancy (elongation form, Ser2P) for AKAP200 and CAPER. All
experiments were performed in triplicate, and results are presented as mean ± SD (*p value < 0.05). Statistical significance was tested by Student’s t
test method
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exon 5 compared to constitutive exon 4 (Fig. 2b and
Additional file 1: Fig. S4A—blue bar). When using the
‘travelled’ index, this represented a steady decline of
PARP1 occupancy from the 5′ constitutive exon 4 to proceeding intron 4–5 and was lowest at the 3′ alternative
exon 5 (Fig. 2b). In PARP1 depleted conditions (PARP1
KD cells), a reduction of ~ 80% of PARP1 occupancy was
measured at alternative exon 5 relative to constitutive
exon 4 (Additional file 1: Fig. S4A—red bar). With the
travelled index incorporated, this change represented a
further decrease of ~ 45% and ~ 80% in PARP1 occupancy
at the proceeding intron 4–5 and at alternative exon
5 relative to the constitutive exon (Fig. 4b—red line). A
similar trend was observed at the CAPER gene though
the decrease in the relative amount of PARP1 occupancy from constitutive exon 3 to alternative exon 4 was
less pronounced. As expected, there was an additional
decrease in PARP1 occupancy at all the tested sites in KD
cells (Fig. 2c and Additional file 1: Fig. S4A).
Next, we asked whether the observed changes in PARP1
occupancy correlate with changes in the occupancy of
RNAPII forms. Using the Ser2P antibody, which recognizes the transcriptionally engaged, elongating form of
RNAPII, we showed that depletion of PARP1 correlated
with depletion of this transcriptionally engaged RNAPII
at the studied exons. These data corroborated our directly
measured results comparing alternative versus constitutive exons and also those measured by the travelled
index. In WT cells, as measured through direct comparison of occupancy at alternative exon versus constitutive
exon, the AKAP gene showed a decrease of ~ 20% (Additional file 1: Fig. S4B). Further supporting these data,
the travelled index (Fig. 2d) showed a steady decline of
Ser2P from the 5′ constitutive exon toward the 3′ alternative exon. These results were very similar for the CAPER
gene (Fig. 2e and Additional file 1: Fig. S4B). Interestingly, in PARP1 knockdown cells, Ser2P decreased even
further (~ 40% at intron 4–5 and alternative exon 5
compared to constitutive exon 4 at AKAP) (Fig. 2d and
Additional file 1: Fig. S4B), while this decrease in Ser2P
was ~ 50% at CAPER gene regions (Fig. 2e and Additional file 1: Fig. S4B). These findings correlated with the
observed decrease in PARP1 occupancy at these sites
(Fig. 2b, c; Additional file 1: Fig. S4A). Next, we asked if
this correlation of PARP1 occupancy is specific for only
the elongating Ser2P occupancy. For this, we tested
the occupancy of the other phosphorylated forms of
RNAPII—the pre-initiating form of RNAPII, also known
as hypo-phosphorylated RNAPII (8WG16), and Ser 5
(4H8). In WT cells, the occupancy of 8WG16 at alternative exons over constitutive exons was reduced by 50%
for both AKAP and CAPER genes, respectively (Additional file 1: Fig. S4C—blue bars). On the other hand, in
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KD cells, we observed an increase in the presence of this
polymerase form (Additional file 1: Fig. S4C—red bars).
Profiling of 4H8, which measures Ser5 which is found
at TSSs and gene bodies, showed a slight increase at the
alternative exon 5 of AKAP compared to the constitutive
exon 4. For CAPER, we observed a large and significant
decrease of ~ 80% occupancy of Ser5 (Additional file 1:
Fig. S4D—blue bars). In KD cells, AKAP exhibited an
increase in this polymerase form while CAPER showed
no significant difference in occupancy compared to WT
cells (Additional file 1: Fig. S4D—red bars). Finally, analysis of the occupancies of PARP1 and the various RNAPII
were recapitulated in cells treated with a second siRNA
(siRNA2), thus confirming the effect of PARP1 on the
occupancy of RNAPII. In contrast, inhibition of PARylation showed no differences in PARP1 or in the occupancies of the different RNAPII forms when compared to
WT cells (Additional file 1: Fig. S5). These data therefore show that PARP1 occupancy and not its PARylation
activity exerts an effect on the occupancy of elongating
polymerase.
PARP1 depletion disrupts chromatin state and structure

Chromatin context can affect the rate of RNAPII elongation, which in turn, would regulate alternative splicing.
After confirming the relationship between PARP1 and
RNAPII pausing, we next investigated the type of chromatin context mediated by PARP1 at these alternative
exon sites. For this, we mapped the nucleosomes across
AKAP and CAPER genes using the nucleosome walking method [32]—a low-resolution technique, which
allows gene-specific high-resolution mapping of nucleosome positions along a stretch of DNA [33]. Chromatin is digested with micrococcal nuclease (MNase) to
yield mostly mononucleosomal fragments and is then
subjected to quantitative real-time PCR (qRT-PCR—
see Methods). First, we predicted nucleosome locations based on sequences alone [34] (Fig. 3a, b—top
panels). Then, primers were designed to amplify about
80–100-bp-sized amplicons that overlapped by 20–40 bp,
tiling across the selected loci of the AKAP and CAPER
genes. In this technique, amplification of a product indicates the presence of a protected mononucleosome,
while the lack of amplification signifies open chromatin
susceptible to MNase digestion. Nucleosome positions
and strength of nucleosome occupancy were then calculated using the fold change between MNase-treated samples and undigested genomic DNA at an equivalent DNA
input concentration (see Methods).
Based on this method, stable and highly reproducible
profiles of nucleosomes were observed across the target
gene region (Fig. 3), with clear differences in the nucleosome profile between WT and PARP1 KD cells. For the
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AKAP gene, two clear observations were made: (1) There
is a strong nucleosome in PARP1 KD cells, mapped by
primer A8, which was previously absent in WT cells.
(2) At the genomic locations mapped by primers A13 to
A15, a reduction in nucleosome occupancy in PARP1 KD
cells was seen, with a shift of the nucleosomes toward the
A16 position (Fig. 3a). For the CAPER gene, we observed
a reduction in nucleosome occupancy just before the
alternate exon 4 (mapped by primers C8–C10) and in
the region containing the alternative exon 4 (mapped by
primers C12–C16) (Fig. 3b). Here too, PARP1 knockdown using siRNA2 produced similar results for nucleosome repositioning as seen in cells transfected with
PARP1 siRNA1, while PARylation-inhibited cells exhibited no changes in nucleosome positioning when compared to WT cells (Additional file 1: Fig. S6). Since these
PARP1-mediated nucleosome rearrangements occur
right before the alternate exon, we posit that PARP1
maintains a chromatin structure that would be amenable
to transcription elongation by RNAPII in the absence of
PARP1.
PARP1 occupancy displays interplay of selective
acquisition of histone methylation at genic regions

Several histone marks have been implicated in alternative splicing [20]. Given that our previous data showed
interplay between PARP1 and certain histone marks
[5], we then sought to determine whether interplay of
PARP1 with specific histones could drive the observed
chromatin rearrangement and transcriptional elongation machinery at the studied regions. Typically, paused
gene regions are marked by bivalent histone marks. In
view of this, we used ChIP-qRT-PCR, to measure the
occupancy for both the activating mark, H3K4me3, and
repressive mark, H3K27me3, in regions that showed the
most change in nucleosome structure—regions mapped
by primers A14 for AKAP and C8 for CAPER and its
surrounding exons (Fig. 3). In WT cells, at both genes,
H3K4me3 and H3K27me3 were found at all sites tested
(preceding constitutive exon, intervening intron, and
alternative exon) with varying levels (Fig. 4). The presence of both the activating H3K4me3 and repressive
mark H3K27me3 is indicative of a poised gene region. To
further assess whether there is interplay between these
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histone marks and PARP1, we investigated whether their
occupancy is changed in the absence of PARP1. Knockdown of PARP1 resolved this bivalency of H3K4me3 and
H3K27me3 marks to H3K4me3. At both of these genes,
there was an increase in H3K4me3 occupancy (Fig. 4a for
AKAP and 4c for CAPER) and a decrease in H3K27me3
occupancy (Fig. 4b for AKAP and 4D for CAPER). The
resultant net gain of H3K4me3—an active histone
mark—possibly opens up the chromatin structure allowing for the passage of transcription machinery. These
data were recapitulated in cells treated with siRNA2
(Additional file 1: Fig. S7—red bars vs. blue bars), while
PARylation-inhibited cells showed no difference relative
to WT cells (Additional file 1: Fig. S7—green bars vs. blue
bars). In summary, our data are consistent with a model
in which binding of the PARP1 mediates or is mediated
by specific histone modifications. Additionally, the effect
of PARP1 on chromatin structure (nucleosome positioning and occupancy of histone PTMs) is instigated by the
direct presence of PARP1 and not its PARylation activity.
Thus, at the sites of alternative splicing, PARP1 could play
a dual role in stimulating the release of RNAPII pausing
and recruiting chromatin modifications that facilitate its
release from the paused state.
PARP1 influences RNAPII elongation genome‑wide

The observations of the direct effect of PARP1 binding on
chromatin structure and histone modification occupancy
prompted us to ask whether PARP1 could influence the
release of RNAPII from pause sites. We used a modified
3′NT-seq method [35] and the NET-seq method [36] to
map the positions of elongating and arrested RNAPII
complexes at nucleotide resolution (Fig. 5a) in the presence and absence of PARP1. The 3′NT method effectively
isolates mRNA from RNA-RNAPII–chromatin complexes. The presence of the m7G cap on RNAPII transcripts within the first 20–30 nucleotides of transcription
allows for the immunoprecipitation of nascent mRNAs
using the GFP-elF4E protein (which binds to the m7G
cap) bound on magnetic beads. These captured mRNAs
were then eluted from beads, purified, and ligated to the
3′ adapter used in Illumina sequencing. Next, the RNAs
were fragmented to not only decap the captured 5′ ends
of the mRNAs, but also to reduce the size of the mRNAs

(See figure on next page.)
Fig. 3 Analysis of nucleosome architecture. The positions of nucleosomes in non-treated cells (WT, blue line) versus PARP1 knockdown (KD, red
line) for the AKAP200 (a) and CAPER (b) genes are distinctive. For each gene, the top panel shows gene region and the predicted nucleosome
location (gray ovals) based on sequence alone [34]. The bottom panel demonstrates the nucleosome position and occupancy (green ovals)
obtained by nucleosome scanning analysis (see Methods). Depletion of PARP1 shifts nucleosome positioning and occupancy. Light green ovals
depict reduction in nucleosome occupancy, while fuzzy nucleosomes are represented as nucleosomes overlying each other. All experiments
were done in triplicate, and results are presented as mean ± SD (results were considered significant as determined by Student’s t test method: p
value < 0.05)
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a
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d

Fig. 4 Knockdown of PARP1 induces dynamic changes in the occupancy of histone marks. The occupancy of activating histone marks (H3K4me3;
lower panels of a, b) at AKAP200 (a) and CAPER (b), and the occupancy of the repressive histone marks (H3K27me3) at AKAP200 (c) and CAPER (d)
were evaluated by ChIP-qPCR for PARP1 target genes. All experiments were performed in triplicate, and results are presented as mean ± SD (p
value < 0.05). Statistical significance was tested by Student’s t test method

to ~ 35–100 nucleotides. Fragmented mRNAs were then
size selected on a denaturing gel. Next, the 5′ phosphate groups were removed enzymatically, allowing for
the ligation of the 5′ sequencing adapter. cDNA libraries were then prepared, and limited PCR amplification
with primers that bind to both the 5′ and 3′ adapters was
performed. This allowed for the capture and sequencing of only mRNA fragments with both the 5′ end (end
after fragmentation) and the original 3′ end of the nascent mRNAs. After PCR, samples were size selected on a
3.3% NuSieve agarose gel. These fragments were treated

and analyzed separately, gel purified, and subjected to
Illumina high-throughput 50 bp paired-end sequencing.
Two biological replicates for WT and PARP1-KD cells
were sequenced, generating ~ 30–100 nt reads for each
3′NT-seq sample (LW1 and its corresponding HW1; LW2
and its corresponding HW2). A total of 780 million reads
were sequenced, 101 million of which mapped uniquely
(i.e., after removing multi-mapped reads and potential
PCR duplicates) to the Drosophila genome (Dm6) after
additional filtering steps.
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Fig. 5 NET-seq results. a A schematic representation of the NET-Seq Illumina library preparation. b Metagene analysis of NET-Seq at different
genomic regions for wild type (WT) and PARP knockdown (KD) cells reveals shortened transcripts (b: orange lines—WT, red lines—KD) and
lengthened transcripts (c): purple and violet lines—WT, blue lines–KD). d Visualization of gene ontology: biological process categories of PARP1
effecting of RNAPII activity

In 3′NT-seq experiments, the sequenced read density reflects the abundance of the transcript and the 3′
ends of the nascent mRNAs map the RNAPII position

at nucleotide resolution. Thus, assuming there is no degradation, these sequenced RNAs would have the captured 3′ ends of the elongating polymerase just before
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transcription elongation inhibition by alpha-amanitin. In
fact, the resolution afforded by 3′NT-seq and the coverage obtained should provide an in-depth view of genomewide transcriptional activity. Thus, to begin our analyses,
we first compared the reproducibility of the biological
replicates using the multiBamSummary tool from DeepTools 2.0 [37]. The biological replicate libraries show
strong agreement (Pearson’s coefficient > 0.988), which
documents the robustness of our approach. We then
compared the sequencing reads normalized by reads per
kilobase of transcript, per million mapped reads (RPKM)
between WT and PARP1 KD cells. To determine if transcription of specific segments of mRNA genes is targeted
by PARP1, we calculated the number of normalized reads
for all mRNA genes and divided them into five separate
regions: 1000 bases immediately upstream of the start
codon (upstream); transcript (from transcription start
sites (TSS) to transcription end sites); first 100 bp of
the transcript; last 100 bases of the transcript; and 1000
bases downstream of the transcript end (downstream).
A total of 100 bins were created for each region. In
the initial global test, using a cutoff of p < 0.01, subtle
differences between WT and PARP1 KD samples were
observed in the bins for the upstream and transcript
regions (Additional file 1: Fig. S8A, B). On the other
hand, some differences were observed at downstream
regions as well as at the early (first 100 nt) and late gene
bodies (last 100 nt) due to PARP1 knockdown (Additional file 1: Fig. S8C–E). Next, using the difference in
the percentage of reads occurring in the first 50 bins,
we filtered the differentially expressed regions into three
groups: Group 1: genes with reads that were shortened;
Group 2: genes with reads that were lengthened; Group 3:
genes with reads that had differential patterns not specifically related with shortening or lengthening. This analysis
resulted in a total of 1786 genes, of which 348 (Group 1)
and 307 (Group 2) had lengthened and shortened transcripts, respectively, in KD versus WT cells, and the rest
were placed in Group 3. We show the top 20 shortened
(Additional file 1: Table S1) and lengthened genes (Additional file 1: Table S2). Examples of shortened and lengthened genes are shown in Additional file 1: Fig. S9A and B,
respectively.
To better understand the pattern of these lengthened
and shortened genes, we also performed metagene analysis of the 3′NT-seq at different genomic regions. We
observed a shifting of RNAPII locations, evidenced by
average RNAPII densities in the PARP1 KD, which were
substantial, often decreasing (shortened) or increasing
(lengthened) (Fig. 5b & c), when compared to the same
sites in WT cells. In the KD condition, when transcripts
have shortened RNAPII profiles, there is a slight shift
in the peak of RNAPII location toward the 5′ end of the
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gene relative to WT (Fig. 5b). For lengthened genes, one
main peak (location) of RNAPII was observed in WT
cells. In PARP1 depleted cells, there was a decrease in
this peak with a concurrent appearance/increase of a
new peak located 3′ of this peak (Fig. 5c), resulting in two
prominent peaks.
At the upstream regions, in genes with a shortened
RNAPII profile, one peak was detected with little to no
change in PARP1 KD cells (Additional file 1: Fig. S10A).
As for the lengthened genes, several peaks were present.
In cells with depleted PARP1, there was a reduction in the
peaks at the 5′ region with a concurrent increase in the
peaks at the 3′ end (Additional file 1: Fig. S10B). A similar
situation occurred for the RNAPII downstream regions
with shortened genes (Additional file 1: Fig. S10C). On
the other hand, slight differences were detected with
lengthened genes, including a stronger peak emerging
toward the 5′ of the WT RNAPII positions (Additional
file 1: Fig. S10D). At the other gene regions, the first and
last 100 bp gene regions, a shortened RNAPII profile can
be seen, similar to the downstream regions (Additional
file 1: Fig. S10E and G, respectively). With the lengthened
genes, there seems to be a flattening and merging of the
two RNAPII peaks in PARP1 KD cells for the RNAPII
locations within the first and last 100 bp genic regions
(Additional file 1: Fig. S10F and H). According to other
studies, a fast polymerase is typically associated with an
overall flattening of the RNAPII profile in the termination zone replacing the clear drop-off in RNAPII density
that occurs in WT cells. Interestingly, such a flattened
profile has been associated with reduced pausing [38].
Finally, we asked whether these genes with shortened or
lengthened transcript regions are involved in any functional pathways. For this we performed gene ontology:
biological process analysis (GO:BP) using categoryCompare [39]. GO:BP analysis results showed that genes with
a shortened RNAPII profile were significantly enriched in
genes associated with cell processing (Fig. 5d and Additional file 1: Table S3). On the other hand, the genes with
a lengthened RNAPII profile were significantly involved
with organismal organization (Fig. 5d and Additional
file 1: Table S4).
We also provide NET-seq analyses on our candidate
genes, AKAP and CAPER. Prominent peaks of RNAPII
density are seen at specific nucleotides or within narrow regions, possibly indicative of pause sites (locations where RNAPII is detected with high probability).
For AKAP (Fig. 6a), NET-seq showed a prominent peak
at the 5′ of the region, with more RNAPII footprints
downstream. Of interest, in KD cells, the main 5′ peak
is absent, with more RNAPII footprints downstream
compared to WT. Indeed, the last nucleotide added is
further along the gene. These results suggest that after
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Fig. 6 Graphic representations of the RNAPII NET-seq results at (a) AKAP and (b) CAPER. RNAPII localization signals normalized as NET-seq read
count signals. Blue arrows indicate the position the final nucleotide added by RNAPII, while green arrow indicates the movement of the polymerase
(c). ‘Kinetic model’ of PARP1–chromatin binding effects on RNAPII elongation, with consequences in alternative splicing regulation. PARP1 creates
and/or maintains a chromatin structure, which is poised for transcription elongation. This structure enables RNAPII to pause, allowing enough
resident time for RNAPII and its associated splicing factors to recognize specific splice sites, resulting in exon inclusion. In the absence of PARP1, the
poised state is resolved to a more active chromatin structure, thus no pausing of the fast RNAPII, resulting in exon skipping. Although this model
can explain our results of lengthening of the transcripts after PARP1 knockdown, it does not explain shortening of transcripts after knockdown
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the PARP1-mediated block is relieved (through knockdown of PARP1), more RNAPII was able to move downstream to selectively include specific exons over others
(Fig. 6a). The situation at the CAPER gene is slightly different. NET-seq in KD cells shows an increase in RNAPII
footprint within the preceding intronic region (left
panel—Fig. 6b), and a slowing down of RNAPII around
the proceeding exonic region located at 7,035,750 bp
(Fig. 6b). These results of a fast RNAPII elongation at
upstream intronic regions and slow down of RNAPII
elongation at the proceeding exons, could explain the
selective exon skipping seen in PARP1 KD cells (Fig. 1b).
Additionally, these results resonate with previous studies
showing that slowing down of RNAPII not only results
in exon inclusion, but has been implicated in exon skipping as well [40]. In summary, our analyses for specific
genes show a clear RNAPII pausing defect (positive and
negative) due to PARP1 depletion. Interestingly, these
changes in RNAPII elongation occur at the same location
of PARP1-mediated chromatin changes (Figs. 3, 4 and
Additional file 1: Figs. S5 and S6), thus supporting our
hypothesis that PARP1-mediated chromatin structural
rearrangement regulates RNAPII elongation and splicing
decisions.

Discussion
Cotranscriptional removal of introns occurs in the vicinity of other gene expression machineries, including
RNAPII and the chromatin remodeling factors. We previously documented that PARP1 is involved in splicing
and proposed that PARP1 might play roles both in the
‘adaptor model’ and in the ‘kinetic model.’ Interestingly,
these models are not mutually exclusive. We showed
that PARP1 influences splicing, in part, through physical interactions of PARP1-bound chromatin, the spliceosome, and RNA. This finding supports the ‘adaptor
model’ of cotranscriptional splicing [5, 11]. However, the
effect of PARP1 on RNAPII elongation in the context of
the ‘kinetic model’ remains unclear. At the beginning of
this study, we proposed that PARP1 might also regulate
RNAPII elongation. This concept is not unreasonable
considering that several studies have shown that PARP1
influences RNAPII pausing at promoters [41], and PARP1
has an impact on negative elongation factor (NELF [42])
during RNAPII elongation. We therefore hypothesized
that PARP1-bound chromatin regulates the RNAPII
elongation rate by maintaining a specific chromatin
structure, thus impacting splicing decisions. In this study,
we undertook a comprehensive investigation of the influence of PARP1 on RNA polymerase elongation and splicing. Although most of this study focused on two target
genes, our data indicate that PARP1-bound chromatin
does influence splicing decisions. The local influence of
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chromatin was illustrated by the experiments on the two
genes of study—AKAP and CAPER. These experiments
showed that depending on the exon under scrutiny, a
given chromatin factor has a variable effect favoring
either exon inclusion or exclusion in a rather unpredictable manner.
Several mechanisms have been proposed to understand
how the rate of RNAPII modulates alternative splicing.
First, this process can occur through the phosphorylation state of the transcribing RNAPII [43] as well as the
association of RNAPII with specific transcription factors
[44]. Second, modulation can occur related to the effect
of chromatin structure on the rate of elongation of the
transcribing RNAPII, through DNA methylation [45] and
histone modifications [12, 40, 46], which could create or
eliminate chromatin roadblocks to elongation. The chromatin structure created impacts splicing decisions. For
instance, increased nucleosome occupancy observed in
exons compared to introns might aid in exon definition
(reviewed in [47]) by modulating the RNAPII elongation
rate. It is also possible that a chromatin context mediated
by PARP1 represents a stumbling block that influences
RNAPII elongation, thereby impacting the outcome of
splicing.
The way that PARP1 affects the RNAPII elongation rate
in vivo is not fully understood. It is possible that PARP1
acts together with other chromatin factors to remodel
the chromatin structure. This could result in opening
up the chromatin structure to influence RNAPII movement, which suggests that a certain degree of nucleosome
remodeling is a prerequisite for, or a consequence of,
active transcription. To investigate the role of PARP1 in
transcriptional elongation and splicing in vivo, we measured the co-occupancy of PARP1 and RNAPII elongating polymerase (Fig. 2). PARP1-bound nucleosomes and
RNAPII occupied similar regions in both genome-wide
studies and in gene-specific loci.
We next determined the structure of the chromatin
bound by PARP1 (Figs. 3, 4 and Additional file 1: Figs. S5
and S6). The nucleosomes bound by PARP1 had both
activating and repressive marks within these two genes.
Typically, the combination of repressive and activating histone marks at promoters, keeps genes expressed
at low levels but poised for rapid activation. Additionally, RNAPII pause sites in transcription elongation
often correlate with positioned nucleosomes [28, 35],
and these nucleosomes are marked by bivalent histone
marks. Thus, the fact that PARP1-bound nucleosomes
within gene bodies displayed both activating and repressive marks indicated that this is a transcriptionally poised
region. Most likely, PARP1-bound chromatin has created a paused region for transcriptional elongation. We
posit these results are instigated directly by PARP1, as
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two siRNAs targeting different regions of PARP1 showed
similar results, while PARylation inhibition had no effect
producing results comparable to WT cells (Figs. 3, 4 and
Additional file 1: Figs. S5 and S6). In fact, once PARP1
was depleted, the remodeling of chromatin structure to
a more open chromatin structure via differential nucleosome occupancy/positioning, and histone modifications,
would allow for transcriptional elongation (Fig. 3). Thus,
our results showing bivalency at PARP1-occupied sites
suggest these are sites of paused transcription, poised for
activation. Another epigenetic mark related to alternative splicing regulation is DNA methylation. Though we
analyzed possible differential DNA methylation changes
at these sites (data not shown), the results were difficult to interpret. We attribute this difficulty to the lack
and//or very low levels of DNA methylation present
in the fly genome [48]. Overall, our data are consistent
with the idea that a chromatin structure mediated by
PARP1, impacts RNAPII elongation and possibly splicing
decisions.
The effect of PARP1 on polymerase elongation and
pausing has been shown in several previous studies. For
instance, at heat shock promoters, immediately after
induction, PARP1 mediates a rapid loss of nucleosomes
in the bodies of induced Hsp70 genes, indicating that
PARP1 acted as a block to transcription elongation.
Immediately after the block is released through PARylation of PARP1 and histones, nucleosomes are remodeled, allowing for polymerase to move along the gene
body with consequences in increased transcript levels
[27, 41, 49]. Interestingly, another study showed that
PARP1 PARylates and inhibits negative elongation factor (NELF), thus illustrating that PARP1 is important in
transcription elongation. The latter study further showed
that knockdown of PARP1 or inhibition of its PARylation
activity, increased RNAPII pausing and reduced productive elongation [42]. These studies therefore provide
functional links between PARP-1, ADP-ribosylation, and
NELF. Furthermore, the binding of PARP1 to nascent
RNA was shown to reduce the rate of RNA elongation
by RNAPII, and subsequent automodification of PARP1
removes the transcriptionally inhibitory PARP1 molecules, thus up-regulating RNA synthesis [50]. Together,
these studies suggest a link between PARP1 and RNAPII
elongation and likely suggest that PARP1 initially would
act as a “bump” to elongating RNAPII. With subsequent
signals, PARP1 gets PARylated, releasing the block to
transcription. PARP1 therefore could act as a hinge
between signaling pathways and gene expression by communicating with the direct regulators of pausing [41,
42, 49]. Our data are consistent with the above studies.
First, we observed that Pro-seq signals of paused RNAPII
are in the same vicinity as PARP1-bound nucleosomes
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genome-wide (Additional file 1: Fig. S3). Sometimes the
RNAPII signal is shifted a little downstream (Additional
file 1: Fig. S3B–D), and the peak becomes broader with
some tailing when compared to the PARP binding peak.
These results hinted to the possibility that PARP1-bound
nucleosomes could be involved in RNAPII elongation
kinetics and possibly that some RNAPII backtracking
occurs at these nucleosomes. RNAPII backtracking has
been suggested to be the rate-limiting step in RNAPII
elongation kinetics [35]. Although we could not definitively show RNAPII backtracking in this study, our
results demonstrate a correlative presence of PARP1
nucleosome and RNAPII peaks within the gene body.
Interestingly, knockdown of PARP1 resulted in loss of
PARP1 signals at target regions with a corresponding loss
of RNAPII signals (Fig. 2 and Additional file 1: Figs. S5
and S6), suggesting that loss of PARP-1 is necessary to
achieve an efficient relieve from the elongation block of
RNAPII into productive elongation.
However, these low-resolution studies do not provide
a detailed understanding of kinetic coupling for the elongation rate, pausing, and nascent RNA structure. We
therefore used a modified version of native elongating
transcript sequencing (NET-seq), combining NET-seq
[36] and 3′NT-seq [35] protocols. Although 3′NT maps
all forms of RNAPII (paused, backtracked, and recovering), it does not map initiating RNAPII. Thus, all our subsequent analyses focused on the regions mapping to the
body of the transcripts, as well as upstream and downstream of the TSS. Our analyses mapping the impact of
PARP1 on the RNAPII location showed that some of the
transcripts were lengthened after PARP1 knockdown
while others were shortened. In comparing our NETSeq data with our previous study on alternative splicing
detected with PARP1-KD RNA-Seq [5] using rMATS
[51], transcripts with shortened sites have twice as many
alternative splice events than those with lengthened sites
or with sites with no change, providing further evidence
that pausing affects alternative splice mechanisms (see
Additional file 2).
Based on our data, we propose a model whereby PARP1
mediates a chromatin structure (nucleosome remodeling and differential occupancies of histone marks) that
slows down the rate of RNAPII elongation, resulting in
enough resident time for RNAPII (Ser2P) and its associated splicing factors to recognize weak splice sites. And
in the absence of PARP1, a more open chromatin structure ensues, allowing fast RNAPII elongation resulting
in exon skipping (Fig. 6c). This model resonates with our
results showing that after PARP1 knockdown, there is a
loss of PARP1-RNAPII co-occupancy (fast RNAPII elongation) with consequences in exon skipping. In some
cases though, we observed shortening of transcripts after
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PARP1 knockdown, indicative of a slowing down of polymerase elongation. Our model though cannot explain
these instances of slow RNAPII and exon skipping in the
absence of PARP1. Thus, further studies will be needed
to tease how PARP1-bound chromatin, by slowing down
the rate of RNAPII elongation, also results in exon exclusion. Generally, the ‘kinetic model’ of RNAPII’s effect on
splicing decisions states that ‘slow RNAPII’ yields exons
that are included while ‘fast RNAPII’ leads to exon skipping. However, contrary to this simplistic interpretation
of the kinetic model, our results show that PARP1–chromatin binding instigates both lengthening and shortening of transcripts. We therefore interpret this effect of
PARP1 on RNAPII elongation and splicing to be context
specific. This interpretation is supported by our recent
studies where we observed both exon inclusion and
exon skipping after PARP1 depletion/PARylation inhibition [5, 11]. In addition, several studies that focused on
the kinetic coupling of splicing and transcription showed
that similar elongation changes promote different splicing outcomes [43, 52, 53]. Thus, changing the elongation
rate may not alter the window of opportunity for positive
splicing factors to bind but may also allow negative splicing factors to bind, justifying why slow RNAPII elongation can also favor exon skipping.

Conclusions
We observed that PARP1 depletion produces skipping of
exons on the AKAP and CAPER genes. RNAPII accumulated at the alternative exons of these genes, which are
potential pause sites that facilitate changes in splicing
[28, 54, 55]. Upon PARP1 depletion, we showed changes
in alternative splicing events and RNAPII accumulation,
suggesting that a correct chromatin structure is required
for the normal splicing events taking place at these alternative exons. The salient question is, why is this region so
sensitive to PARP1 depletion? We analyzed the context of
PARP1 occupying this region (Figs. 3, 4; Additional file 1:
Figs. S5 and S6). In the presence of PARP1, both activating and repressive histone marks are also present in this
region. In addition to RNAPII elongation rate, PARP1bound chromatin may also play a role in recruiting splicing factors. Because PARP1 can post-translationally
modify histones [56, 57], it is possible that the absence
of a correct nucleosomal structure under conditions of
PARP1 depletion might also impair the recruitment of
these splicing factors to the chromatin. Whatever the
case, our data show a link in PARP1 depletion, RNAPII
phosphorylation state, RNAPII elongation state, histone
modification, and nucleosome positioning. In summary,
the results in this study are consistent with the idea that
PARP1 is crucial in gene regulatory processes in the cell.
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Materials
1. S2 cell culture and siRNA-mediated knockdown
Drosophila melanogaster S2 cells (obtained from
Thermo Fisher Scientific, Waltham, MA 02451) were
cultured in Schneider’s Drosophila medium (Life Technologies, Austin, TX 78744) supplemented with 10%
heat-activated fetal bovine serum (Sigma, St Louis, MO
63146), 100 U/ml penicillin, and 100 μg/ml streptomycin at 25 °C. All experimental samples and controls were
growth time and cell-density matched. siRNA-mediated
PARP1 knockdown was performed as described previously [5]. siRNA1 for KD1 was made according to the
Lis laboratory—Cornell University, Ithaca, NY, USA [49],
while siRNA2 was made from PCR products targeting
specific exons of PARP1 and LacZ were obtained from
the Drosophila RNAi Screening Center (FlyRNAi.org—
the database of the Drosophila RNAi screening center:
2012 update) to produce double-stranded RNA (dsRNA)
for PARP1 knockdown and non-targeting control LacZ.
Depletion of PARP1 was confirmed by Western blot and
quantitative PCR using primers 1–4 (Additional file 1:
Table S5).
2. PARylation inhibition
Cells were treated with 10 μM PJ34 hydrochloride
(PARylation inhibitor, Thermo Fisher Scientific, #528150,
Rockford, IL, 61101) or vehicle overnight for 16 h. Cells
were then washed twice with PJ34-free medium, pelleted,
and frozen for experiments.
3. Western blots
Western blots were performed using a standard protocol, and input dilutions were used as a quantitative
indication of signal linearity. Protein samples were resuspended in SDS loading buffer and electrophoresed
on a 10% Tris–glycine gel with Tris running buffer. The
proteins were transferred to PVDF membrane (Thermo
Scientific, Rockford IL, 61101) and sequentially probed
with primary antibodies for PARP1 and actin. Western
blot-based detection was performed using alkaline phosphatase-coupled secondary antibodies (Sigma, St Louis,
MO 63146) with Amersham ECF substrate for visualization (GE Healthcare, Waukesha, WI 53188), and images
were obtained using Typhoon FLA 9500 (GE Healthcare,
Piscataway, NJ 08854). ImageQuant TL software was
used to quantify protein signals.
4. Measurement of poly-ADP-ribose (PAR) level
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PAR assay in cellular extract was done using highthroughput chemiluminescent ELISA (HT PARP in vivo
Pharmacodynamic Assay II kit from Trevigen, #4520096-K, Gaithersburg, MD 20877). Net mean relative light
units (RLU) values of the PAR standards were calculating by subtraction of the background (without PAR) from
RLU values and presented as a function of PAR values
(pg/ml).
5. Chromatin immunoprecipitation (ChIP)
Cross-link chromatin immunoprecipitation (X-ChIP)
protocol was performed with slight modifications. In
brief, 1 × 107 cells were re-suspended in PBS and fixed
with 1% formaldehyde for 10 min. Next, cells were
washed 3 times with cold PBS and pelleted at 1200 rpm.
The cell pellet was re-suspended in lysis buffer (50 mM
HEPES–KOH (pH 7.5); 140 mM NaCl; 1 mM EDTA (pH
8); 1% SDS; 1% Triton X-100; 0.1% sodium deoxycholate and protease inhibitors). After 10 min incubation
on ice, the lysate was sonicated for 20 min (30 s on/30 s
off ) with Bioruptor 300, (Diagenode, Sparta, NJ 07871)
to shear DNA to an average fragment size of 150–700 bp.
Cell debris was pelleted and the supernatant (containing chromatin) was used for immunoprecipitation
(IP)—25 μg of chromatin was used in an IP experiment.
Lysates containing chromatin were diluted 1:10 in RIPA
buffer (50 mM mM Tris–HCl, (pH 8); 150 mM NaCl;
2 mM EDTA (pH 8); 1% NP-40; 0.1% SDS; 0.5% sodium
deoxycholate and protease inhibitors), and 50 μl of chromatin was removed to serve as input. Primary antibodies
(PARP1, S2P, 4H8, 8WG16, H3K4me3, and H3K27me3)
were added to the samples (10 μg per 25 μg DNA) and
rotated at 4 °C for 1 h. Rabbit IgG was used for negative
or non-specific background control. The pre-bound antibody–chromatin complexes were incubated with Protein
A/G Dynabeads (Thermo Fisher Scientific, Waltham, MA
02451) overnight at 4 °C with rotation in the presence of
BSA (0.2 mg/ml). Using a magnetic stand for separation,
all beads were washed twice with low salt buffer (0.1%
SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris–HCl
(pH 8); 150 mM NaCl), then twice with high salt buffer
(0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris–
HCl (pH 8); 500 mM NaCl). In addition, samples were
washed twice with LiCl buffer [0.25 M LiCl; 1% NP-40;
1% sodium deoxycholate; 1 mM EDTA; 10 mM Tris–HCl
(pH 8)]. Finally, specific DNA–protein complexes were
eluted with 120 μl of elution buffer (1% SDS; 10 mM
NaHCO3) for 15 min at 30 °C. The immunoprecipitated
material and chromatin input were subjected to reverse
cross-links according to Abcam X-ChIP protocol, and
DNA was purified using the QIAquick PCR Purification Kit (Qiagen, Gaithersburg, MD 20878). Quantitative

Page 15 of 18

real-time PCR with primers 5–6, 9–10, 13–16, 43–44
(intron 4–5), 77–78 (intron 3–4) (Additional file 1:
Table S5) was used to identify the level of specific DNA
fragments from the immunoprecipitated DNA. All sets
of primers were designed using Integrated DNA Technologies Primer Tools. Real-time, quantitative PCR (RTqPCR) analysis was performed using CFX96 Real-Time
System (Bio-Rad) with Taq DNA polymerase (MB042EUT-10000, Syd Labs, Natick, MA 01760) and EvaGreen
dye (Biotium). Reactions were performed at 25 μl and
cycling parameters are as follows: 4 min at 94 °C, followed by 40 cycles of 45 s at 94 °C, 30 s at 60 °C and 60 s
at 72 °C. For quality control purposes, melting curves
for all samples were acquired (10 s at 95 °C and 60 s at
60 °C). For qPCR analysis, fold enrichment was measured
against the IgG negative control and values were normalized to ChIP input.
6. Antibodies
For Western blot analysis:
Primary antibodies: PARP1 C terminal, rabbit (#39561,
Active Motif, Carlsbad, CA 92008); Actin, mouse monoclonal (MA1-744, Thermo Fisher Scientific, Waltham,
MA 02451). Secondary antibodies: anti-rabbit and antimouse IgG (whole molecule); alkaline phosphatase antibody (Sigma).
For ChIP:
PARP1, rabbit (#39561, Active Motif, Carlsbad,
CA 92008); H5 (S2P), mouse monoclonal (ab24758,
Abcam, Cambridge, MA 02139); 4H8 mouse monoclonal (ab5408, Abcam, Cambridge, MA 02139); 8WG16,
mouse monoclonal (ab817, Abcam, Cambridge, MA
02139); H3K4me3, mouse monoclonal (ab1012, Abcam,
Cambridge, MA, USA 02139); H3K27me3, mouse monoclonal (ab6147, Abcam, Cambridge, MA 02139), and
for non-specificity control: Rabbit IgG (I8140; SigmaAldrich, St Louis, MO 63146).
7. PCR to measure isoform expression
Total RNAs were isolated from each sample using the
RNeasy Plus Mini kit from Qiagen (Gaithersburg, MD
20878). 1 μg of RNA per reaction was used for reverse
transcription reaction using iScript reverse transcriptase
(Bio-Rad Laboratories, Hercules, CA 94547). The resultant cDNAs were used in PCR (S1000 Thermal Cycler,
Bio-Rad) with the indicated primer sets (Additional file 1:
Table S5: primers 5, 8, 9 and 12). PCR cycling parameters
were as described in the Chromatin Immunoprecipitation
section. PCR products were analyzed on 3.3% NuSieve
agarose gel (Lonza, Rockland, ME 04841) with GelStar
Nucleic Acid Gel Stain (Lonza, Rockland, ME, 04841)
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and visualized with Typhoon FLA 9500 (GE Healthcare,
Piscataway, NJ 08854). ImageQuant TL software was
used to quantify cDNA signals and calculate relative isoform expression. Splice isoforms were confirmed by cloning the products from PCR analyses using PCR Cloning
Kit (NEB) according to the manufacturer’s protocol and
sequenced by Eurofins Scientific.
8. Micrococcal (MNase) digestion of chromatin and
DNA purification
Chromatin was digested at 27 °C using a predetermined
concentration of MNase (Sigma-Aldrich). Digestion was
stopped by adding 1/10th the volume of stop solution
[10% of SDS and 0.5 mM EDTA (pH 8)]. Samples were
further digested with RNAse A (Goldbio) and proteinase
K (Sigma-Aldrich) to remove contaminating RNAs and
proteins. DNA was finally purified as described in the
Chromatin Immunoprecipitation section.
9. Nucleosome scanning analysis
The resulting purified DNA samples from MNase
digestion were electrophoretically separated on 3.5%
NuSieve agarose gel (Lonza), and mononucleosomesized (140–200 bp) fragments were excised from the gel
and purified using QIAquick PCR purification kit (Qiagen). Obtained DNA was analyzed using a ‘nucleosome
walking’ technique. A set of overlapping primer pairs,
each of which generate 100–120 bp PCR products that
are located 20–40 bp away from neighboring primer pairs
(Additional file 1: Table S5, primers 17–84), was used to
analyze nucleosome positions. For every primer pair,
the real-time PCR results (both of DNA isolated from
nucleosomes and of naked DNA digested by micrococcal
nuclease) were placed on a quantitative scale by comparison to serial dilutions of a known concentration of undigested genomic DNA, used as an absolute standard.
10. Genes of interest
AKAP200 (Flybase ID: FBgn0027932, symbol:
CG13388)
CAPER (Flybase ID: FBgn0031883, symbol: CG11266)
11. Net-seq 3′NT library preparation
Nascent RNA isolation was performed as described
by Weber et al. [35], and cap selection was done as
described by Ya-Lin Chiu et al. [58] using GFP-elF4E
recombinant protein generously provided by Dr. G.
Zentner, Indiana University. RNA:GFP-elF4E complexes
were isolated using GFP-nAb Magnetic Agarose beads
(Allele Biotech) according to the manufacturer’s protocol. Sequencing library preparation for nascent RNA
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samples was performed according to the Illumina Protocol with slight modifications. After 3′-SR adaptor ligation, RNA was fragmented to 30–100 nucleotides with
the RNA Fragmentation Reagent (Albion, AM8740)
and purified according to Mayer et al. [36]. In order to
prevent RNA fragments ligation, we performed 3′-OH
phosphorylation with T4 PNK (3′ phosphatase minus)
before hybridization of reverse transcription primer and
5′-SR adaptor ligation. After reverse transcription with
superscript reverse transcriptase (Invitrogen), we purified cDNA on 15% polyacrylamide TBE-urea gel to avoid
primer dimer formation, excised the gel region between
50 and 300 nt and extracted cDNA. After PCR amplification, we performed quality control (QC) and size
selection. To be confident, we cloned and sequenced the
PCR products using Zero Blunt TOPO PCR Cloning kit
(Thermo Fisher Scientific). Positive colonies were harvested; plasmid DNA was purified with QIAprep Spin
Miniprep kit (Qiagen) and digested with EcoR1. Digested
products were visualized on 1% agarose gel and sent for
sequencing (Eurofins Scientific). After positive confirmation, accumulated cDNA was sent for sequencing by
HiSeq 4000 Illumina platform.
12. Processing and alignment of sequencing reads
Nucleosome sequencing and analyses were done as
in Matveeva et al. 2016 [5]. Details on processing and
analyses of NET-seq are found in supplementary materials and methods.

Additional files
Additional file 1. Supporting materials and methods section, includ‑
ing supplementary Figures 1–10 and supplementary Tables 1–6
Additional file 2. Western blot images of the full gel images found in
Additional file 1: Supplementary Fig. S1
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